Tyenne

Increased risk of serious or fatal infections (eg, TB, bacterial, invasive fungal, viral, and other opportunistic infections); if develop, interrupt until controlled. Active infections: do not give therapy. Consider risks/benefits prior to initiating: chronic or recurrent, or history of opportunistic infections, exposed to TB, travel to, or residence in, areas with endemic TB or mycoses, or conditions that predispose to infection. Monitor closely for signs/symptoms of infection during and after therapy; interrupt if serious or opportunistic infection or sepsis develop. Test for and treat latent TB prior to starting therapy. HBV or HCV infection. For RA, GCA: ANC <500mm³, platelets <50000mm³, or ALT/AST >5×ULN: not recommended; obtain LFTs before initiation, every 4–8 weeks after starting for the 1^st 6 months, then every 3 months thereafter; and monitor neutrophils, platelets: 4–8 weeks after initiation, then every 3 months thereafter. Monitor lipids 4–8 weeks after initiation, then subsequently according to clinical guidelines. Monitor neutrophils, platelets, ALT/AST for SJIA: at the time of the 2^nd administration and then every 2–4 weeks; PJIA: at the time of the 2^nd administration and then every 4–8 weeks. Increased risk for GI perforation. Immunosuppression. Malignancies. CNS demyelinating disorders; monitor. Discontinue permanently if anaphylaxis or other hypersensitivity reactions occur. Active hepatic disease or impairment: not recommended. Severe renal impairment. Elderly. Pregnancy. Nursing mothers.